CytomX Therapeutics (CTMX) Projected to Post Quarterly Earnings on Thursday

CytomX Therapeutics (NASDAQ:CTMX) is expected to release its earnings data before the market opens on Thursday, March 6th. Analysts expect CytomX Therapeutics to post earnings of ($0.23) per share and revenue of $13.53 million for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

CytomX Therapeutics Trading Up 0.3 %

Shares of NASDAQ:CTMX opened at $0.68 on Friday. The business has a 50-day moving average price of $0.89 and a 200 day moving average price of $1.04. The company has a market capitalization of $53.00 million, a price-to-earnings ratio of 3.98 and a beta of 1.01. CytomX Therapeutics has a 12-month low of $0.66 and a 12-month high of $5.85.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of CytomX Therapeutics in a research report on Tuesday, January 7th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $5.77.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.